Startup entity
All 1 tracked stories fall under one category: acquisition. Wellgistics Health Inc. is most often covered alongside Neuritek Therapeutics, Inc., which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.7 across the same-window beat baseline.
Last mentioned: Mar 23, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: acquisition. Wellgistics Health Inc. is most often covered alongside Neuritek Therapeutics, Inc., which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.7 across the same-window beat baseline. The 7 average consequence score is above the beat benchmark of 6.6 in the same window. We currently track 1 Startup story that mention Wellgistics Health Inc., all published on March 23, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 38 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Wellgistics Health Inc.. Shared-story counts are live from our verified record — not editorial picks.
Wellgistics Health Inc. has signed a $105 million Letter of Intent to acquire Neuritek Therapeutics, a biotech firm specializing in neurological and psychiatric disorder treatments. The deal marks a significant strategic pivot for Wellgistics into the high-stakes central nervous system (CNS) therapeutic market.
Wellgistics Health Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
